|The 1M trade on Friday and today's 200K trade can't be pi's as we wouldn't be able to get a price within the Bid / Ask spread as both of those trades were.
Fund / Institution selling in order to cover withdrawals or need funds to buy a "bargain" ....!!|
|Just joking bam. I'm not feeling a bit like selling. Would buy more if I didn't mind knocking my portfolio completely out of balance!|
|From the Interims 12-10-2016:
Alongside this, we continue to progress with our European market entry and expect to be in a position to launch our first orthopaedic product, OrthoPure(TM) XT, into this market in H1 2017, with CE mark submission expected to be made a full six months ahead of schedule.
The developing momentum behind our dCELL(R) Technology product portfolio brings us confidence that we will achieve our year end corporate goals. We look forward to reporting our progress in the coming months."
So more news in the coming months...............time to add, or at worse, just to sit tight imo and wait for the share price to increase. Personally I added 2 more small lots on the recent dip which has now exhausted all spare cash that was sitting in my ISA account.|
|No. I'm not selling. I still have my original holding.|
|So we should sell then, bamboo?!😜|
On the projected figs I think the co can last another approx 18 months. TRX will need a dilutive fund raising, another partnership or bid to absorb the costs of going into production for dCell Meniscus/ACL.
The new products that will be released next year, will take time to gain traction in the medical community.|
|Who is off loading a Million shares at 13-30pm today then ?????????????????|
|Sales way up, but so are the losses. But think a moment: both a lot of sales and costs are abroad, in $ and €; so being a loss making business right now whilst building up, that will make the numbers look worse with the £ having dropped so much since B-day. Stepping back and looking more objectively at what the business is about, I see that they are a year or two away from turning a profit, but have the cash and resources to get through that period, and thereafter be a successful and profitable company, with very high barriers to entry. This isn't an income or trading stock, but a good longer term capital gain share to hold. And at current prices, a chance to buy or add. In fact, fill your boots at current price levels!! All IMHO, DYOR.|
|With the current cash balance and exponential sales growth they just MIGHT avoid the need for a further share issue. But it'll be tight and depends on how fast R&D rises.|
|I suppose not to bad? Momentum on the sales front is building, but so are cost, so there'll be no clash for some time. Hence a money raise some time soon?|
|We have to hope that these estimates are conservative. [ie they need to beat]
"12-month revenue guidance range has been narrowed to $2.5m -$3.5m compared to the 12-month prior period of $1.2m (however, please note shortened accounting period below). "
"As noted previously the Group has changed its accounting reference date to 31 December. The next reporting period will therefore be for the 11 months to 31 December 2016. "|
|Unaudited Interim Results for the six months ended 31 July 2016
Leeds, 12(th) October 2016 - Tissue Regenix Group (AIM:TRX) "Tissue Regenix" or "The Group", the regenerative medical devices company, today announces its unaudited interim results for the six months ended 31 July 2016.
During the period, the Group has achieved the following important milestones:
-- Delivered revenue of GBP631k (2015: GBP252k) 150% increase
-- 510(k) Market clearance for SurgiPure(TM) XD
-- First dCELL(R) process approval by the FDA
-- OrthoPure(TM) XT regulatory process shortened
-- First GPO contract signed in the US for DermaPure(R)
-- Further Medicare approvals for DermaPure(R) - 93% now covered
-- Appointment of VP Orthopedics North America
Antony Odell, CEO of Tissue Regenix Group plc commented: "Tissue Regenix delivered revenue of GBP631k during the six months to 31(st) July 2016, a 150% increase over the comparative period. Our continued focus on adoption and advocacy was rewarded with further Medicare approvals and our first Group Purchasing Order agreement, both significant steps for the continuing success of DermaPure(R), and highlights the growing commercial traction DermaPure(R) has gained within the competitive US wound care market.|
|Based at the time of writing then from the last 20 trades none are showing as buys, but from a process of elimination then I would say 16 of them are BUYS and only 4 are sells. This is based on my "dummy" buys during this time. Nothing for "the big boys" to hoover up just before Results..........!!!|
|In auction. That's something.|
|One thing is for sure, running costs will be higher. Just hope income can meet some of it and that income and running costs will clash very soon?
As long as it all looks very promising, then I'll be happy.|
|Well price action tells us nothing ! Generally I expect results to disappoint when they have been preceded by a price rise, and surprise to the upside when preceded by a share price decline. So, we can expect results to be solid without inspiring us, then ?!!|
|To top-up or not to top-up now, that is the question !!!!!!!!!!!!!!!!|
|Results out Wednesday
We'll see if the wide range of estimates from management for Dermis are on target
Hoping for an update on the Ortho CE mark.|
|Good news at BTG this morning! I've got a strange feeling about where things are heading at some time in the future!|
|Notice of Interim Results Wednesday 12 October
Leeds, 28 September 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today gives notice that it will announce its interim results for the six months ending 31 July 2016, on Wednesday 12(th) October.|
|swiss, I agree. Given that the co has a broad range of treatments, and that there aren't that many pharmas that would want all of them, splitting the co into three divisions a while ago makes this quite plausible.|
|so am surmising the Edison research report did not light fires under anyone. My initial thoughts are that this is a flag up saying come and buy us - we have products but we will not be in profit for another couple of years.
Anyone think anything else?|
|LEEDS, England--(Business Wire)--Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”) will publish for the first time retrospective analysis on wound care product DermaPure® providing real world evidence of its use in clinical practice.
Retrospective Observational Analysis of the Use of an Architecturally Unique Dermal Regeneration Template (DermaPure®) for the Treatment of Hard-to-Heal Wounds by Kimmel, Howard, Gittleman, Haley, is now available online and will feature in the ‘International Wound Journal’, the first time a US physician has published a DermaPure® study in a peer reviewed journal.
The data which has been collated from 37 patients across 29 treatment centres, mainly focusses on the use of DermaPure® in the treatment of chronic wounds such as Diabetic Foot Ulcers (DFU) 37.8% and Venous Leg Ulcers (VLU’s) 18.9%, with the remaining patients being treated for either traumatic or surgical wounds.
At the time of application, the average wound size was 12.88cm2 and had been present for 56 weeks. The end point of the study was considered to be once complete closure was established, something which was achieved with one application of DermaPure in an average time of 10.58 weeks.
The retrospective data analysed proved to be consistent with what has been observed in published studies previously undertaken by NHSBT in the UK and showed complete healing for:
DFU’s - 52% at 4 weeks
73% at 8 weeks
85% at 12 weeks
Average time to heal 8.21 weeks
VLU’s - 49% at 4 weeks
70% at 8 weeks
81% at 12 weeks
Average time to heal 11.29 weeks
When compared with two other retrospective trials of acellular dermis used to treat DFUs DermaPure® was proven to heal more effectively with fewer applications.
Alongside this, a study undertaken at the University of Manchester looking into gene expression and the effect that this has on healing chronic wounds has been published in ‘Wound Repair and Regeneration’.
The findings of this research, led by Dr. Ardeshir Bayat, is of particular importance as optimal wound healing is dependent upon appropriate gene expression. The outcome of this study has confirmed that by applying DermaPure® to a chronic wound, such as a DFU, post debridement, the wound is converted to an acute wound, allowing the body to progress naturally through the wound healing cycle. Chronic wounds that did not receive this treatment had different gene expression and remained unable to advance appropriately through the healing process. Thus, proving a treatment such as DermaPure® to have a significant advantage when treating patients suffering with chronic wounds, such as DFU’s, where the amputation rate can be as high as 15%.
Greg Bila, President, Tissue Regenix Wound Care Inc. said: “The publication of this clinical data is key in highlighting the problems physicians face when treating chronic wounds, and how regenerative treatments such as DermaPure® address, and potentially revolutionize, the outlook for these patients. Many times products illustrate outcomes in the study environment that are seldom seen in the real world clinical environment. However, we now have two substantive pieces of research that illustrate the effectiveness of Tissue Regenix dCELL® Technology in the treatment of chronic and acute wounds, and demonstrates the potential effectiveness of this technology in other areas of healthcare.”
A full copy of the peer reviewed paper is available here,
|Quite why we have this thread I do not know! Some threads overdo it one way, but this one certainly under-does it by a mile.👉ӿ99;😡|